SymbolLUCD
NameLUCID DIAGNOSTICS INC.
SectorHEALTH CARE
RegionNorth America
IndustryMedical/Dental Instruments
Address60 EAST 42ND STREET,SUITE 4600, NEW YORK, New York, 10165, United States
Telephone+1 212 949-4319
Fax
Email
Websitehttps://www.luciddx.com
IncorporationUNDEFINED
Incorporated On
Employees
Fiscal Year
Public Since
ExchangesNASDAQ
Auditor
Audit StatusNOT PROVIDED
Reporting Status
CIK0001799011
Description

Lucid Diagnostics Inc is a commercial-stage medical diagnostics technology company focused on the millions of patients with gastroesophageal reflux disease, also known as chronic heartburn, acid reflux, or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically highly lethal esophageal adenocarcinoma. Its products include EsoCheck and EsoGuard.

Additional info from NASDAQ:
Lucid Diagnostics Inc is a commercial-stage medical diagnostics technology company focused on the millions of patients with gastroesophageal reflux disease, also known as chronic heartburn, acid reflux, or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically highly lethal esophageal adenocarcinoma. Its products include EsoCheck and EsoGuard.

2026-08-13 12:23

(30% Negative) LUCID DIAGNOSTICS INC. (LUCD) Reports Q3 2026 Financial Results

Read more
2026-08-13 12:00

Lucid Diagnostics Provides Business Update and Reports Second Quarter 2026 Financial Results

Read more
2026-08-13 12:00

Lucid Diagnostics Provides Business Update and Reports Second Quarter 2026 Financial Results

Read more
2026-08-05 12:48

Lucid Diagnostics Secures Commercial Coverage Policy Spanning Multiple Health Plans for its EsoGuard® Esophageal DNA Test

Read more
2026-08-04 12:32

Lucid Diagnostics to Participate in Upcoming Investor Conferences

Read more
2026-07-30 12:30

Lucid Diagnostics to Hold Second Quarter 2026 Business Update Conference Call and Webcast on August 13, 2026

Read more
2026-06-24 21:00

(99% Neutral) LUCID DIAGNOSTICS INC. (LUCD) Announces Executive Changes

Read more
2026-05-21 20:20

Director Matheis Dennis 🟢 acquired 245.0K shares of Lucid Diagnostics Inc. (LUCD) at $1.00 Transaction Date: May 20, 2026 | Filing ID: 000217

Read more
2026-05-14 12:05

(30% Negative) LUCID DIAGNOSTICS INC. (LUCD) Reports Q2 2026 Financial Results

Read more
2026-05-14 12:00

Lucid Diagnostics Provides Business Update and Reports First Quarter 2026 Financial Results

Read more
Trial ID Title Phase Indication Status Start Date Completion Date Source
NCT06532734 Barrett's Esophagitis in Anorexia Nervosa Binge/Purge Subtype Barrett Esophagus Recruiting 2024-11-12 2026-11-01 ClinicalTrials.gov
NCT05778851 Clinical Utility of a Non Endoscopic Device EsoCheck and Biomarker EsoGuard as … Na Barrett Esophagus Completed 2023-04-12 2024-08-19 ClinicalTrials.gov
NCT05965999 Lucid Registry Study Barrett Esophagus Unknown 2023-04-11 2024-06-01 ClinicalTrials.gov
NCT06030180 CLUE: CLinical Utility Study of EsoGuard Na Barrett Esophagus Completed 2023-02-23 2024-12-13 ClinicalTrials.gov
NCT04311970 Pilot Study of Esocheck in Eosinophilic Esophagitis Na Eosinophilic Esophagitis Completed 2020-08-05 2021-08-23 ClinicalTrials.gov
NCT04295811 Efficacy of EsoGuard Assay on Esophageal Surface Cells Collected With EsoCheck … Na Barrett Esophagus Unknown 2020-06-18 2023-12-01 ClinicalTrials.gov
NCT04293458 Efficacy of EsoGuard on Samples Collected Using EsoCheck Versus EGD for the Dia… Na Barrett Esophagus Completed 2020-02-28 2022-08-22 ClinicalTrials.gov
Total clinical trials: 7
Product Name Type Development Stage Therapeutic Area Study Status Trial ID
EsoCheck Other Approved Eosinophilic Esophagitis COMPLETED NCT04311970
Esophagogastroduodenoscopy Other Approved Barrett Esophagus UNKNOWN NCT04295811
EsoGuard (lab assay) Other Approved Barrett Esophagus UNKNOWN NCT04295811
EsoGuard Other Approved Barrett Esophagus COMPLETED NCT04293458
EsoCheck Other Preclinical Barrett Esophagus UNKNOWN NCT05965999
EsoGuard Other Approved Barrett Esophagus COMPLETED NCT06030180
EsoGuard result Other Approved Barrett Esophagus COMPLETED NCT05778851
EsoGuard Other Preclinical Barrett Esophagus RECRUITING NCT06532734
EsoGuard result DEVICE Approved Barrett Esophagus COMPLETED NCT05778851
EsoCheck DEVICE Preclinical Barrett Esophagus UNKNOWN NCT05965999
EsoGuard (lab assay) DEVICE Approved Barrett Esophagus UNKNOWN NCT04295811
EsoGuard DEVICE Preclinical Barrett Esophagus RECRUITING NCT06532734
Total products: 12